VanEck Biotech ETF
BBH
116 hedge funds and large institutions have $143M invested in VanEck Biotech ETF in 2024 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 23 increasing their positions, 34 reducing their positions, and 7 closing their positions.
71% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 7
68.34% more ownership
Funds ownership: 33.48% → 101.82% (+68%)
3% more funds holding
Funds holding: 113 → 116 (+3)
6% less capital invested
Capital invested by funds: $151M → $143M (-$8.64M)
32% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 34
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GA
GFS Advisors
Houston,
Texas
|
+$289M |
| 2 |
Wells Fargo
San Francisco,
California
|
+$9.85M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.74M |
| 4 |
ACA
Atlas Capital Advisors
Jackson,
Wyoming
|
+$932K |
| 5 |
Jones Financial Companies
Des Peres,
Missouri
|
+$434K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$10.9M |
| 2 |
VWM
Valley Wealth Managers
Paramus,
New Jersey
|
-$3.21M |
| 3 |
Envestnet Asset Management
Chicago,
Illinois
|
-$3.14M |
| 4 |
CIG
Consolidated Investment Group
Englewood,
Colorado
|
-$2.21M |
| 5 |
Jane Street
New York
|
-$1.66M |
BBH Hedge Fund Activity: Q2 2024 in Review
116 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in VanEck Biotech ETF (BBH) for Q2 2024, worth a combined $143M — down 5.7% from $151M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new BBH positions and 7 closed out — a net gain of 5 holders — while 23 added to existing stakes and 34 trimmed.
The largest buyer was GFS Advisors, opening a new position worth an estimated $289M. The largest seller was JP Morgan Chase, cutting an estimated $10.9M.
- 116 institutional investors held VanEck Biotech ETF (BBH) as of Q2 2024, up from 113 in Q1 2024.
- Funds reported $143M of VanEck Biotech ETF stock for Q2 2024, down 5.7% quarter-over-quarter.
- 12 funds opened new VanEck Biotech ETF positions in Q2 2024 and 7 closed out, a net change of +5 holders.
- The largest VanEck Biotech ETF buyer in Q2 2024 was GFS Advisors, an estimated $289M added.
- The largest VanEck Biotech ETF seller in Q2 2024 was JP Morgan Chase, an estimated $10.9M sold.
Based on aggregated 13F filings for Q2 2024.